Cancer is one of the major healthcare challenges across the globe. Several anticancer
drugs are available on the market but they either lack specificity or have poor safety, severe …

Currently, chemotherapy remains the standard treatment for first-and second-line
management of small cell lung cancer (SCLC). Immunotherapy has made progress in the …

Introduction Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination …

Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …

Angiogenesis has always been the topic of major scientific interest in the field of malignant
tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by …

PURPOSE No combined immunotherapy and antiangiogenic therapy have been
investigated in exclusively programmed death-ligand 1 (PD-L1)–positive advanced cervical …

Abstract Treatment of non-small cell lung cancer (NSCLC) harboring epidermal growth
factor receptor (EGFR) activating mutation with EGFR-TKIs has achieved great success, yet …

The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …

Purpose: Anlotinib has achieved good results in clinical trials of a variety of cancers.
However, the effects of anlotinib on the tumor microenvironment (TME) and systemic …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …